key: cord-0896555-5wz5brls
authors: Araki, Takashi; Morimoto, Ryota; Ito, Ryota; Mizutani, Takashi; Kimura, Yuki; Kazama, Shingo; Oishi, Hideo; Kuwayama, Tasuku; Hiraiwa, Hiroaki; Kondo, Toru; Okumura, Takahiro; Murohara, Toyoaki
title: A Case of Systemic Capillary Leak Syndrome with Severe Cardiac Dysfunction after mRNA Vaccination for COVID-19
date: 2022-03-24
journal: CJC Open
DOI: 10.1016/j.cjco.2022.03.008
sha: 742126a55d287618abc91d648f0127601a8a3431
doc_id: 896555
cord_uid: 5wz5brls

A 53-year-old woman with no significant medical history developed cardiogenic shock four days after receiving the second dose of the COVID-19 mRNA vaccine (BNT162b2, Pfizer/BioNtech). The patient required extracorporeal membrane oxygenation and an Impella device. Based on significant hemoconcentration, decreased plasma protein levels, and pathological findings in myocardial specimens, the patient was diagnosed with vaccination-induced fulminant systemic capillary leak syndrome (SCLS) with severe cardiac dysfunction. This Case highlights that SCLS can occur after COVID-19 mRNA vaccination and may be associated with cardiac dysfunction. In patients with cardiogenic shock, hemoconcentration, and hypoalbuminemia after vaccination, SCLS should be considered.

Cardiogenic shock with systolic dysfunction and global myocardial edema requiring venoarterial 2 extracorporeal membrane oxygenation and Impella was observed in a patient after COVID-19 3 mRNA vaccination (BNT162b2). Based on findings such as hemoconcentration, 4 hypoalbuminemia, and no obvious inflammatory cell infiltration on myocardial biopsy, we 5 diagnosed systemic capillary leak syndrome, and pulsed steroid therapy resulted in rapid 6 improvement in cardiac function. The patient required extracorporeal membrane oxygenation and an Impella device. Based on 4 significant hemoconcentration, decreased plasma protein levels, and pathological findings in 5 myocardial specimens, the patient was diagnosed with vaccination-induced fulminant systemic 6 capillary leak syndrome (SCLS) with severe cardiac dysfunction. This case highlights that SCLS 7 can occur after COVID-19 mRNA vaccination and may be associated with cardiac dysfunction. 8

In patients with cardiogenic shock, hemoconcentration, and hypoalbuminemia after vaccination, 9 SCLS should be considered. Pfizer/BioNTech) four days prior to admission. Fever occurred on the day after the vaccination 5 and resolved two days later. However, general malaise and loss of appetite worsened, requiring 6 transportation to the emergency department of the initial hospital. On admission to the initial 7 hospital, there were no other symptoms, such as hives, flushing and conjunctival swelling to 8 suggest anaphylaxis. Systolic blood pressure was 66 mmHg and heart rate was 139 beats/min. 9

Hemoglobin, Troponin-T, and BNP levels were remarkably elevated (20.8 g/dL, 7.6 ng/mL, 10 1676 pg/mL, respectively). Left ventricular ejection fraction (LVEF) was significantly reduced 11 to 17% with severe myocardial edema noted on echocardiogram. After infusion of noradrenaline 12 Furthermore, no opening of the aortic valve was observed, which was caused by the afterload 5 due to ECMO retrograde blood flow (Video 1). The IABP was replaced with an Impella CP 6 device to prevent left ventricular thrombosis and reduce the left ventricular end-diastolic 7 pressure. At the time of the Impella CP insertion, the activated partial thromboplastin time 8 (aPTT) was significantly prolonged, reflecting coagulation abnormalities despite not receiving 9 heparin since arrival. Three myocardial biopsies from the right ventricular septum were 10 performed to differentiate myocarditis. Hematoxylin and eosin staining of the myocardial tissues 11 revealed no inflammatory cell infiltration and limited injuries within the myocardium. 12

Immunostaining also detected no immuno-positive cells (Figure 2) . A significant decrease in 13 plasma proteins was detected, including albumin (0.8 g/dL), complement (C3: 12.2 mg/dL, C4: 14 4.5 mg/dL), γ-globulin (IgG: 184 mg/dL, IgA: 28 mg/dL, IgM: 30 mg/dL), and coagulation 15 factors (prothrombin time-international normalized ratio: 1.75, antithrombin-Ⅲ (AT-Ⅲ): 26.0%, 16 fibrinogen: 102 mg/dL), which reflected an increase in vascular permeability. Additionally, the 17 blood pressure could not be maintained without a large dose of noradrenaline even with 18 sufficient ECMO flow, making us suspect a significantly decreased vascular resistance. We 1 diagnosed the patients with SCLS with severe cardiac dysfunction based on decreased blood 2 pressure, low albumin, and hemoconcentration without inflammatory findings in myocardial 3 pathology. 4

Intravenous corticosteroids (methylprednisolone 500 mg twice a day) were administered for 5 three days to improve vascular hyperpermeability and vascular resistance, in addition to 6 vasopressin for maintaining blood pressure. From the next day, cardiac function improved 7 rapidly, and catecholamine and vasopressin were gradually reduced. On the fourth day, ECMO 8 was removed, and the Impella CP was removed on the following day. Blood, sputum, and urine 9 cultures of samples collected at admission, and various polymerase chain reaction tests for 10 viruses in the myocardium were all negative. Magnetic resonance imaging showed no evidence 11 of late gadolinium enhancement. Although the patient's weight had increased by approximately 12 15 kg from baseline, it was rapidly improved by diuretics. 13

After progressive reduction in dosage, corticosteroids were discontinued on the 23rd day 14 without re-exacerbation of cardiac dysfunction or altered hemodynamics. The LVEF improved to 15 68%, although some pericardial effusion persisted (Video 2). Although it is difficult to make a strict distinction between FM and SCLS, we finally diagnosed 9 SCLS with severe cardiac dysfunction based on our findings of hemoconcentration and a marked 10 reduction in plasma proteins. SCLS has been reported after receiving adenovirus vector 11 (ChAdOx1 nCOV-19, Ad26.COV2.S) and mRNA (mRNA-1273, BNT162b2) vaccines against 12 COVID-19. Although only one case of SCLS per 13 million ChAdOx1 nCOV-19 vaccine doses 13 has been reported in Europe, the precise number of cases requiring mechanical circulatory 14 support is unclear. 4-6 SCLS is reported to be caused by drugs such as human recombinant 15 interleukin-2 (IL-2) and interferons, hematological malignancies, infectious diseases such as 16 COVID-19 and influenza, and autoimmune diseases. Up to 79% of adult patients with SCLS 17 have monoclonal gammopathy of undetermined significance (especially IgG kappa); however, 18 such involvement was not detected in this case. The mortality rate of SCLS is 20-30%, and 1 treatment includes steroids and high-dose intravenous immunoglobulins. 2 The exact etiology of 2 vaccine-associated SCLS remains unknown. After vaccination, a strong response of CD8+ and 3 CD4+ T cells and production of interferon γ and IL-2 have been observed, and an association 4 between IL-2 and SCLS has been reported. 7 Thus, immune response to the vaccination may be 5 involved in SCLS; however, further research is needed to verify the cause. 6

In our patient, significant prolongation of aPTT and reduction of plasma proteins, including 7 coagulation factors such as AT-Ⅲ and fibrinogen, were observed at the time of admission. 8

Although the cross-mixing test was not performed, all plasma protein levels normalized after 9 recovery. Thus, we hypothesized that these issues were caused by the leakage of coagulation 10 factors rather than production of autoantibodies. Multiglandular hormone deficiency has been 11 reported in a patient with SCLS. 8 Although thyroid and adrenal hormone levels were normal 12 after improvement of cardiac function in our patient, multiglandular hormones might have been 13 deficient due to extravasation. Therefore, in addition to suppressing the immune response 14 described above, prompt pulsed steroid therapy might have been effective against adrenal 15 insufficiency caused by extravasated proteins. 16

Even if there are no abnormalities such as anaphylaxis immediately after vaccination, attention 1 should be paid to serious complications such as myocarditis and SCLS during the initial days 2 after vaccination. 

Fulminant myocarditis and systemic 2 hyperinflammation temporally associated with BNT162b2 mRNA COVID-19

vaccination in two patients

Capillary leak syndrome: state of the art 5 in 2021

Myocardial involvement in systemic capillary 7 leak syndrome: first demonstration by pathologic findings

Systemic capillary leak syndrome after ChAdOx1 nCOV-10 19 (Oxford-AstraZeneca) vaccination

Fatal systemic capillary leak syndrome after SARS-12

COV-2vaccination in patient with multiple myeloma

Severe exacerbations of systemic capillary 15 leak syndrome after COVID-19 vaccination: a case series

J o u r n a l P r e -p r o o f